High Vista Strategies LLC Iveric Bio, Inc. Transaction History

High Vista Strategies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $1.09 Million - $1.64 Million	41,458 Added 42.26%	139,552 $5.49 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $1.1 Million - $1.53 Million	64,034 Added 188.0%	98,094 $2.1 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $224,274 - $443,538	-23,859 Reduced 41.19%	34,060 $611,000
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $39,544 - $81,950	4,336 Added 8.09%	57,919 $557,000
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $577,866 - $800,451	-47,561 Reduced 47.02%	53,583 $902,000
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $526,051 - $714,334	38,037 Added 60.27%	101,144 $1.69 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $394,916 - $977,515	-55,858 Reduced 46.95%	63,107 $1.03 Million
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $125,692 - $158,385	-22,090 Reduced 15.66%	118,965 $751,000
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $121,894 - $165,325	23,995 Added 20.5%	141,055 $872,000
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $119,130 - $161,511	21,085 Added 21.97%	117,060 $809,000
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $384,859 - $603,682	95,975 New	95,975 $541,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.